402 related articles for article (PubMed ID: 19804687)
1. Omalizumab for the treatment of severe persistent allergic asthma.
Jones J; Shepherd J; Hartwell D; Harris P; Cooper K; Takeda A; Davidson P
Health Technol Assess; 2009 Sep; 13 Suppl 2():31-9. PubMed ID: 19804687
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.
Walker S; Burch J; McKenna C; Wright K; Griffin S; Woolacott N
Health Technol Assess; 2011 May; 15 Suppl 1():13-21. PubMed ID: 21609649
[TBL] [Abstract][Full Text] [Related]
3. Infliximab for the treatment of adults with psoriasis.
Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
7. Ustekinumab for the treatment of moderate to severe psoriasis.
Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for the treatment of rheumatoid arthritis.
Bagust A; Boland A; Hockenhull J; Fleeman N; Greenhalgh J; Dundar Y; Proudlove C; Kennedy T; Moots R; Williamson P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():23-9. PubMed ID: 19804686
[TBL] [Abstract][Full Text] [Related]
9. Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal.
Jones ML; Holmes M
Health Technol Assess; 2009 Sep; 13 Suppl 2():15-21. PubMed ID: 19804685
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
[TBL] [Abstract][Full Text] [Related]
11. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
Dewilde S; Turk F; Tambour M; Sandström T
Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
[TBL] [Abstract][Full Text] [Related]
12. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
13. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
14. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
Dal Negro RW; Tognella S; Pradelli L
J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
[TBL] [Abstract][Full Text] [Related]
15. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective.
Campbell JD; Spackman DE; Sullivan SD
Allergy; 2010 Sep; 65(9):1141-8. PubMed ID: 20148804
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.
Brown R; Turk F; Dale P; Bousquet J
Allergy; 2007 Feb; 62(2):149-53. PubMed ID: 17298423
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
Sullivan SD; Turk F
Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib for the treatment of multiple myeloma patients.
Green C; Bryant J; Takeda A; Cooper K; Clegg A; Smith A; Stephens M
Health Technol Assess; 2009 Jun; 13 Suppl 1():29-33. PubMed ID: 19567211
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands.
van Nooten F; Stern S; Braunstahl GJ; Thompson C; Groot M; Brown RE
J Med Econ; 2013; 16(3):342-8. PubMed ID: 23216016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]